December 18, 2009
The death rates of children with HIV have decreased ninefold since doctors started prescribing cocktails of antiretroviral drugs in the mid-1990s, concludes a large-scale study of the long-term outcomes of children and adolescents with HIV in the United States. In spite of this improvement, however, young people with HIV continue to die at 30 times the rate of youth of similar age who do not have HIV, found researchers from the National Institutes of Health and other institutions.
Earlier studies have shown that adults with HIV are living longer because of improved multi-drug antiretroviral regimens known as highly active antiretroviral therapy (HAART). However, limited information has existed about the effectiveness of HAART in improving the survival of children with HIV. The current analysis, published in the Dec. 15 issue of the Journal of Acquired Immune Deficiency Syndromes, delineates the effects of HAART on the rates and causes of death for HIV-infected children and adolescents.
Conducted by the Pediatric AIDS Clinical Trials Group, the study was co-funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Allergy and Infectious Diseases (NIAID), both part of NIH. The studys first author is Michael T. Brady, M.D., of Nationwide Childrens Hospital in Columbus, Ohio.
Although this represents a dramatic improvement in survival, the death rate for children with HIV is approximately 30 times higher than that of similarly aged U.S. children who do not have HIV. Multi-organ failure and kidney disease are now major causes of death for HIV-infected children and adolescents. Infections also continue to cause deaths in this group of patients. However, the type of infections has changed, from infections traditionally associated with AIDS to infections that are more common in children without HIV infection.
"The findings are very encouraging, but they still show a need for improvement," said Alan Guttmacher, M.D., acting director of NICHD. "For both adults and children, combination antiretroviral therapy is highly effective in preventing the opportunistic infections and other complications resulting from HIV infection. We must now better understand and pursue treatments for children and adolescents to address the other conditions resulting from HIV infection."
"Basic research and clinical studies funded by NIH beginning in the 1980s laid the foundation for the development of the more than two dozen drugs now available to fight HIV, enabling many children infected with the virus to live into adulthood," said NIAID Director Anthony S. Fauci, M.D. "Now we face the challenge of effectively treating the consequences of long-term HIV infection in people who have been infected since childhood."
Between 1993 and 2006, the researchers tracked 3,553 U.S. children and adolescents infected with HIV. Of those children, 298 died. Growing numbers of children with HIV began receiving HAART between 1994 and 2000, and death rates declined annually during that period. Nearly 60 percent of all deaths in the study occurred before 1997, before the advent of HAART for the treatment of children; moreover, children who died were almost four times as likely to have never received HAART as those who survived.
"A wonderful change has occurred: Most HIV-infected children now reach adulthood," said Lynne Mofenson, M.D., an author of the paper and chief of the Pediatric, Adolescent and Maternal AIDS branch at NICHD. "Will these children have a normal lifespan? Unfortunately, we dont have all the answers yet. Currently, we dont have the means to prevent all the complications of HIV infection."
In the early years of the study, secondary infections killed more than one-third of the children who died, but from 2002 to 2006, that proportion fell to less than one-fourth. Over time, children and adolescents with HIV became more likely to die of kidney failure, stroke, or AIDS-induced multiple organ failure.
To try to prevent these deaths, another long-term study of children with HIV called the Pediatric HIV/AIDS Cohort Study is being funded by NICHD, NIAID, the National Institute on Drug Abuse, the National Institute on Deafness and Other Communication Disorders, the National Heart, Lung, and Blood Institute, and the National Institute of Mental Health. This study is monitoring how children and adolescents with the virus grow and develop, what complications they experience, and whether they experience side effects from their medication.
"To keep these children healthy, we need to learn more about how HIV and anti-HIV drugs affect their growing bodies," said Dr. Mofenson. "We took a big leap in our understanding with this study, and the next pediatric cohort study will lead to even more improvements in understanding HIV infection and its treatment in youth."
In addition to Drs. Brady and Mofenson, the other authors of the article are James M. Oleske, M.D., M.P.H., of the University of Medicine and Dentistry of New Jersey; Paige L. Williams, Ph.D., of the Harvard School of Public Health; Carol Elgie of Frontier Science Technology and Research Foundation; Wayne M. Dankner, M.D., of Parexel International and Duke University Medical Center, and Russell B. Van Dyke, M.D., of Tulane University.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.